Faber Anthony C, Chiles Thomas C
Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Int J Oncol. 2006 Dec;29(6):1561-6.
Resveratrol is a polyphenolic compound that exhibits anti-proliferative and anti-inflammatory activities. BCL6, a transcriptional repressor frequently translocated in lymphomas, including diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (FL), regulates germinal center B-cell differentiation. We report herein that resveratrol treatment of human LY8 follicular lymphoma cells leads to an accumulation of LY8 cell in G0/G1 phase and apoptosis. Resveratrol decreased the expression of BCL6 protein, concomitant with the increased expression of several BCL6 regulated gene products, including p27, p53 and CD69. In addition, resveratrol reduces Myc expression in LY8 cells. These results demonstrate for the first time that resveratrol inhibits a BCL6-linked pathway and suggest that loss of BCL6 expression may represent a key event underlying the anti-proliferative activities of resveratrol on LY8 cells. The use of resveratrol to treat aggressive lymphomas with BCL6 and/or MYC translocations may prove useful as an effective therapy.
白藜芦醇是一种具有抗增殖和抗炎活性的多酚类化合物。BCL6是一种转录抑制因子,在包括弥漫性大B细胞淋巴瘤(DLBCL)和转化型滤泡性淋巴瘤(FL)在内的淋巴瘤中经常发生易位,它调节生发中心B细胞的分化。我们在此报告,用白藜芦醇处理人LY8滤泡性淋巴瘤细胞会导致LY8细胞在G0/G1期积累并凋亡。白藜芦醇降低了BCL6蛋白的表达,同时几种受BCL6调节的基因产物的表达增加,包括p27、p53和CD69。此外,白藜芦醇降低了LY8细胞中Myc的表达。这些结果首次证明白藜芦醇抑制了与BCL6相关的途径,并表明BCL6表达的缺失可能是白藜芦醇对LY8细胞抗增殖活性的关键事件。使用白藜芦醇治疗具有BCL6和/或MYC易位的侵袭性淋巴瘤可能被证明是一种有效的治疗方法。